What Takeda's Failed TOMMORROW Trial Means For Early Alzheimer's Today
The TOMMORROW study was revolutionary for its time in testing Actos early, before symptoms are apparent; failure is disappointing but similar metabolic approaches might still play a role, says the Alzheimer's Association.
You may also be interested in...
Karuna Upbeat On New Antipsychotic Mechanism Data
Karuna Therapeutics’ top-line Phase II data for a combination of a centrally acting muscarinic agonist, xanomeline, and a peripherally acting muscarinic antagonist, trospium, were greeted with enthusiasm by investors and the Boston, MA-based biotech.
Private Longeveron Bets On Stem Cells For Inflammation, Aging Diseases
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.
Pharmas Join To Build Inflammation Biomarkers In Alzheimer's, Depression
Drug firms exploring link between inflammation and central nervous system disorders are now sharing resources through public/private Biomarkers Consortium project.